Skip to Content

Tag Archives: Merck

June 2007 Issue

Rodney Dangerfield may be gone, but Wall Street’s “I don’t get no respect” bull market is keeping his legacy alive. Dow at another new all-time high? Shrug. Takeovers spiking stocks left and right? Yawn. We’re in the midst of what ought to be a rollicking party, and most of the guests are half-asleep!
To be honest with you, I’m delighted with this state of affairs. It suggests that the advance will last longer, and climb to far greater heights, than the majority of observers now expect. When this bull is ready to keel over, it will be from too much revelry�not an excess of caution.
In this month’s visit, I’ll show you how to pinpoint the safest, most value-packed stocks in this underappreciated market. Remarkably, some of my top candidates are household names, giants “hidden in plain sight.” I’ve got three for you that could easily pop 20%�30% in the coming year, with even bigger gains down the road.

December 2006 Issue

Gridlock! Whether you’re delighted or dismayed by the results of the midterm election, I’ve got encouraging news for you—a divided government in Washington isn’t such a bad thing for your investments. This month, I’ll show you how you can take advantage of the new paths to profit that the election has opened up. In fact, I expect gains of 40%-60% in the next two years for my top picks. December also marks the fourth anniversary of our Incredible Dividend Machine. This nifty portfolio has beaten the overall stock market by such a huge margin it’s almost amusing. In our latest lineup, I’m swapping two of the members of the Machine with new names that I’m confident will keep the streak going. Finally, the holiday season is the perfect time to do some housecleaning, and if you’re sitting on a mutual fund that has outlived its usefulness, raise a glass of holiday cheer and toast it good-bye. Then replace it with one of my four best funds for your specific needs.

June 2006 Issue

In this month’s visit, I’ll show you where these bargains lie buried. I’ll also give you an update on our ever-popular income feature, the Incredible Dividend Machine. A boon for retirees, the Machine lets you earn a dividend check every month of the year, with low turnover (minimal exposure to capital gains taxes) and none of the ongoing expenses of a mutual fund.

MAJOR BOTTOM FOR DRUG STOCKS?

For a number of weeks, P/E ratios (and other valuation yardsticks) for the big-name pharmaceutical stocks have shriveled to multiyear lows. Now we seem to be approaching a downside climax.

WHAT'S THE TRUTH ABOUT CELEBREX?

Wall Street was wringing its hands again today over Pfizer (NYSE: PFE). A report in a Canadian newspaper, the National Post, said PFE’s pain-killing arthritis drug, Celebrex, was linked to 14 deaths. The article cited documents that Canadian health authorities use to track adverse reactions to drugs.

WHAT’S THE TRUTH ABOUT CELEBREX?

Wall Street was wringing its hands again today over Pfizer (NYSE: PFE). A report in a Canadian newspaper, the National Post, said PFE’s pain-killing arthritis drug, Celebrex, was linked to 14 deaths. The article cited documents that Canadian health authorities use to track adverse reactions to drugs.

MAINE'S MEDICINE

Is this a good time to buy drug stocks? It’s a natural question for contrarians in the wake of the Supreme Court decision Monday. Pharmaceutical stocks nosedived after the court lifted an injunction preventing the state of Maine from going ahead with its prescription-drug plan. Maine wants to offer 20% discounts on medicine for citizens who don’t belong to an insurance program that includes drug coverage.

MAINE’S MEDICINE

Is this a good time to buy drug stocks? It’s a natural question for contrarians in the wake of the Supreme Court decision Monday. Pharmaceutical stocks nosedived after the court lifted an injunction preventing the state of Maine from going ahead with its prescription-drug plan. Maine wants to offer 20% discounts on medicine for citizens who don’t belong to an insurance program that includes drug coverage.